logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

AACR 2018 — Durvalumab + tremelimumab combo shows antitumor activity in urothelial cancer

Tremelimumab may improve response rates to second-line durvalumab in metastatic disease.